NGNE (neurogene.com) Nilai bisnis marang pendapatan

Logo perusahaan publik Neurogene Inc (NGNE)

The absence of current cash flows and R&D expenditures contrast with a powerful defensive barrier in the form of gene therapy patents. The EV/Sales ratio indicates a risk of asset overheating, where the 0.00 mark records this metric. In the future, the capitalization of Neurogene Inc. (NGNE) will rely on the commercialization of innovative pediatric drugs following the completion of clinical trials.

NGNE neurogene.com: Rasio nilai perusahaan marang pendapatan ing interval 23.11.2025 - 20.11.2026

Rincian metrik keuangan lan pasar Neurogene Therapeutics (NGNE)

- rega lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
Analisis wiwitan perusahaan:Neurogene Inc., NGNE
Produk asil prodhuksi Neurogene Corp

For the biotechnology sector, revenue-based valuation determines a company's market potential while accounting for its liabilities. Current EV/Sales dynamics compare the total enterprise value with sales volume, excluding the impact of debt load. This indicator reveals asset overvaluation relative to actual cash flows. For Neurogene Inc. (NGNE), this calculation reflects budget management efficiency during the development of gene therapies. It is critical for investors to track deviations of this metric from the average to assess stagnation risks.

Analisis pesaing Neurogene Inc.

BIIB (Biogen Inc.) - Rasio nilai perusahaan marang pendapatan|NBIX: Multiplikator EV/Sales|RGC (Regencell Bioscience Holdings Limited) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Axsome Therapeutics Inc|ACAD: Nilai bisnis marang pendapatan|Multiplikator EV/Sales XENE|Multiplikator EV/Sales vikingtherapeutics.com (VKTX)|Rasio nilai perusahaan marang pendapatan Supernus SUPN|Nilai bisnis marang pendapatan CPRX|denalitherapeutics.com - Multiplikator EV/Sales|Rasio total nilai perusahaan marang pendapatan Harmony Pharma HRMY|BHVN: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - Multiplikator EV/Sales|Rasio nilai perusahaan marang pendapatan PRAX (Praxis Medicines)|Rasio nilai perusahaan marang pendapatan Anavex Life Sciences (AVXL)|Rasio nilai perusahaan marang pendapatan CBLL (CeriBell EEG)|Multiplikator EV/Sales PRTA (Prothena Corp)|alector.com (ALEC) - Multiplikator nilai perusahaan marang pendapatan|ANNX: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Omeros|ACIU: Multiplikator EV/Sales|VYGR - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Neumora Therapeutics, Inc.|Rasio nilai perusahaan marang pendapatan SCLX (Scilex)|Nilai perusahaan marang pendapatan TVGN (Tevogen Bio)|Multiplikator EV/Sales Alpha Cognition Inc (ACOG)|Multiplikator EV/Sales CGTX (cogrx.com)|Rasio total nilai perusahaan marang pendapatan Inhibikase Pharma (IKT)|SAVA: Nilai perusahaan marang pendapatan|Rasio total nilai perusahaan marang pendapatan Assertio ASRT|COYA (coyatherapeutics.com) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan VTGN|OVID (Ovid Therapeutics) - Multiplikator EV/Sales|Acumen Pharmaceuticals, Inc (ABOS) - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan CervoMed, Inc. (CRVO)|ATHE - Multiplikator nilai perusahaan marang pendapatan|Multiplikator EV/Sales CLNN (Clene Inc.)|Rasio total nilai perusahaan marang pendapatan PepGen Inc. (PEPG)|JUNS - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Relmada Corp|ANVS (Annovis Bio, Inc.) - Nilai perusahaan marang pendapatan|Grace Tx (GRCE) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan AIFF|Multiplikator EV/Sales anewmeds.com|Rasio nilai perusahaan marang pendapatan NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Nilai bisnis marang pendapatan|MetaVia - Nilai perusahaan marang pendapatan|NRXS: Rasio nilai perusahaan marang pendapatan|Helius Medical Technologies, Inc. - Multiplikator EV/Sales|PASG: Rasio nilai perusahaan marang pendapatan|Neuphoria (NEUP) - Rasio nilai perusahaan marang pendapatan|Minerva Neurosciences - Nilai bisnis marang pendapatan|ATHA (Athira Pharma, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan addextherapeutics.com ADXN|Nilai perusahaan marang pendapatan ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Nilai bisnis marang pendapatan|Multiplikator EV/Sales PTIX (Protagenic)|Multiplikator EV/Sales pasitheaclinics.com KTTA|CRGT - Rasio nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan ATXI (Avenue Therapeutics)|BCLI: Multiplikator EV/Sales|Cara Therapeutics - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Chromocell Therapeutics Corporation|Multiplikator EV/Sales Eliem Therapeutics Inc.|Rasio nilai perusahaan marang pendapatan Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Nilai bisnis marang pendapatan|Multiplikator EV/Sales MRNS (marinuspharma.com)|NKGN: Rasio nilai perusahaan marang pendapatan|NRBO - Rasio nilai perusahaan marang pendapatan|SAGE - Multiplikator EV/Sales|Synaptogenix (SNPX) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Trevena (TRVN)|Nilai perusahaan marang pendapatan VIGL|Rasio nilai perusahaan marang pendapatan WENA (Anew Medical)|Multiplikator EV/Sales CERE